Physicians

ADAPT® products – sold globally (subject to regulatory approval) under the product names CardioCel, CardioCel Neo, CardioCel 3D and VascuCel – are currently used by surgeons around the world to treat patients with congenital heart defects and those in need of heart valve, vessel and cardiovascular repairs.

Tissue bio-implants developed using the ADAPT® tissue engineering process more closely mimic the characteristics of normal human tissue which promotes a more tolerant immune response with improved tissue ingrowth.

Tissue exposed to the ADAPT® process has been shown to have significantly improved functionality and lasting durability.

With the potential for a product lifespan free from calcification, clinicians can potentially intervene across a broader age spectrum and provide their patients with a solution for life.

It has regulatory approval for sale in Europe, North America, Canada, Hong Kong, Malaysia, Singapore, New Zealand, India and the Middle East and North Africa Region. CardioCel® is also available under the special access scheme in Australia and other select countries.

We also offer a range of high quality infusion solution and medical products to help facilitate efficient patient pain management, mobility and discharge.

About Admedus

Admedus is a global healthcare company that develops, commercialises and distributes next generation medical technologies and devices. Our mission is to provide patients around the world with a better quality of life through access to our leading medical solutions and products